Association between six genetic variants of IL-17A and IL-17F and cervical cancer risk: a case–control study

Tumor Biology

Volumn 36, Issue 5, 2015, Pages 3979-3984

  Lv, Qiongying ^a   Zhu, Dingjun ^a   Zhang, Juan ^a   Yi, Yuexiong ^a   Yang, Shujuan ^b   Zhang, Wei ^a  

^a RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

Cervical cancer; Interleukin 17; Single nucleotide polymorphism

Indexed keywords

GENOMIC DNA; INTERLEUKIN 17; INTERLEUKIN 17F;

ADULT; ARTICLE; CANCER PATIENT; CANCER RISK; CANCER STAGING; CASE CONTROL STUDY; CONTROLLED STUDY; DNA EXTRACTION; ENVIRONMENTAL FACTOR; FEMALE; GENE FREQUENCY; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; GENOTYPE ENVIRONMENT INTERACTION; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; MAJOR CLINICAL STUDY; MIDDLE AGED; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; UTERINE CERVIX CANCER; AGED; GENETIC PREDISPOSITION; GENETICS; PATHOGENICITY; PATHOLOGY; UTERINE CERVIX TUMOR; VIROLOGY;

ADULT; AGED; CASE-CONTROL STUDIES; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; INTERLEUKIN-17; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; UTERINE CERVICAL NEOPLASMS;

EID: 84929966584     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-015-3041-y     Document Type: Article

References (33)

1. International Agency for Research on Cancer. GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx.
2. Wen C. China’s plans to curb cervical cancer. Lancet Oncol. 2005;6:139–41.
3. Schlecht NF, Kulaga S, Robitaille J, et al. Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia. JAMA. 2001;286:3106–14.
4. Woodman CB, Collins S, Winter H, et al. Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. Lancet. 2001;357:1831–6.
5. Quan Y, Zhou B, Wang Y, et al. Association between IL17 polymorphisms and risk of cervical cancer in Chinese women. Clin Dev Immunol. 2012;2012:258293.
6. Shi TY, Zhu ML, He J, et al. Polymorphisms of the Interleukin 6 gene contribute to cervical cancer susceptibility in Eastern Chinese women. Hum Genet. 2013;132(3):301–12.
7. de Waal MR, Haanen J, Spits H, et al. Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J Exp Med. 1991;174(4):915–24.
8. Fernandes AP, Gonçalves MA, Duarte G, Cunha FQ, Simões RT, Donadi EA. HPV16, HPV18, and HIV infection may influence cervical cytokine intralesional levels. Virology. 2005;334(2):294–8.
9. Shi WJ, Liu H, Wu D, Tang ZH, Shen YC, Guo L. Stratification analysis and case–control study of relationships between interleukin-6 gene polymorphisms and cervical cancer risk in a Chinese population. Asian Pac J Cancer Prev. 2014;15(17):7357–62.
10. Chen X, Han S, Wang S, et al. Interactions of IL-12A and IL-12B polymorphisms on the risk of cervical cancer in Chinese women. Clin Cancer Res. 2009;15(1):400–5.
11. Yang YC, Chang TY, Chen TC, Chang SC, Lin WS, Lee YJ. Genetic variants in interleukin-18 gene and risk for cervical squamous cell carcinoma. Hum Immunol. 2013;74(7):882–7.
12. Chagas BS, Gurgel AP, da Cruz HL, et al. An interleukin-10 gene polymorphism associated with the development of cervical lesions in women infected with human papillomavirus and using oral contraceptives. Infect Genet Evol. 2013;19:32–7.
13. Kolls JK, Linden A. Interleukin-17 family members and inflammation. Immunity. 2004;21(4):467–76.
14. Kawaguchi M, Adachi M, Oda N, Kokubu F, Huang SK. IL-17 cytokine family. J Allergy Clin Immunol. 2004;114(6):1265–73. quiz 1274.
15. Wu D, Wu P, Huang Q, Liu Y, Ye J, Huang J. Interleukin-17: a promoter in colorectal cancer progression. Clin Dev Immunol. 2013;2013:436307.
16. Cua DJ, Tato CM. Innate il-17-producing cells: the sentinels of the immune system. Nat Rev Immunol. 2010;10:479–89.
17. Yang L, Qi Y, Hu J, Tang L, Zhao S, Shan B. Expression of Th17 cells in breast cancer tissue and its association with clinical parameters. Cell Biochem Biophys. 2012;62:153–9.
18. Lan C, Huang X, Lin S, et al. High density of IL-17-producing cells is associated with improved prognosis for advanced epithelial ovarian cancer. Cell Tissue Res. 2013;352:351–9.
19. Meng XY, Zhou CH, Ma J, Jiang C, Ji P. Expression of interleukin-17 and its clinical significance in gastric cancer patients. Med Oncol. 2012;29:3024–8.
20. Chechlinska M, Kowalewska M, Nowak R. Systemic inflammation as a confounding factor in cancer biomarker discovery and validation. Nat Rev Cancer. 2010;10:2–3.
21. Iwakura Y, Ishigame H, Saijo S, Nakae S. Functional specialization of interleukin-17 family members. Immunity. 2011;34:149–62.
22. Matsuzaki G, Umemura M. Interleukin-17 as an effector molecule of innate and acquired immunity against infections. Microbiol Immunol. 2007;51:1139–47.
23. Kao CY, Chen Y, Thai P, et al. Il-17 markedly up-regulates beta-defensin-2 expression in human airway epithelium via JAK and NF-kappaB signaling pathways. J Immunol. 2004;173:3482–91.
24. Kaabachi W, ben Amor A, Kaabachi S, Rafrafi A, Tizaoui K, Hamzaoui K. Interleukin-17A and -17F genes polymorphisms in lung cancer. Cytokine. 2014;66(1):23–9.
25. Zhang X, Zheng L, Sun Y, Zhang X. Analysis of the association of interleukin-17 gene polymorphisms with gastric cancer risk and interaction with Helicobacter pylori infection in a Chinese population. Tumour Biol. 2014;35(2):1575–80.
26. Omrane I, Marrakchi R, Baroudi O, et al. Significant association between interleukin-17A polymorphism and colorectal cancer. Tumour Biol. 2014;35(7):6627–32.
27. Li N, Zhu Q, Li Z, et al. IL17A gene polymorphisms, serum IL-17A and IgE levels, and hepatocellular carcinoma risk in patients with chronic hepatitis B virus infection. Mol Carcinog. 2014;53(6):447–57.
28. Wang L, Jiang Y, Zhang Y, et al. Association analysis of IL-17A and IL-17F polymorphisms in Chinese Han women with breast cancer. PLoS One. 2012;7(3):e34400.
29. Chen Z, Ding J, Pang N, et al. The Th17/Treg balance and the expression of related cytokines in Uygur cervical cancer patients. Diagn Pathol. 2013;8:61.
30. Souza JM, Matias BF, Rodrigues CM, Murta EF, Michelin MA. IL-17 and IL-22 serum cytokine levels in patients with squamous intraepithelial lesion and invasive cervical carcinoma. Eur J Gynaecol Oncol. 2013;34(5):466–8.
31. Wu TC, Kurman RJ. Analysis of cytokine profiles in patients with human papillomavirus-associated neoplasms. J Natl Cancer Inst. 1997;89:185–7.
32. Kadish AS, Timmins P, Wang Y, et al. Regression of cervical intraepithelial neoplasia and loss of human papillomavirus (HPV) infection is associated with cell-mediated immune responses to an HPV type 16 E7 peptide. Cancer Epidemiol Biomarkers Prev. 2002;11:483–8.
33. Scott M, Stites DP, Moscicki AB. Th1 cytokine patterns in cervical human papillomavirus infection. Clin Diagn Lab Immunol. 1999;6:751–5.